In the field of cancer research one researcher has made it his mission to not only cure the disease but help alleviate both the pain and the cost for patients. In his studies, Mikhail Blagosklonny has focused specifically on the connection between aging and cancer and the correlation between an increased age and likelihood of developing cancerous cells. Blagosklonny works as a professor at Roswell Park Institute as a professor of oncology. He started his professorship at New York Medical College in 2002 and received his medical degree and Ph.D. at First Pavlov State Medical University focusing in experimental medicine and cardiology. Before his move to Roswell, He served as the senior scientist at Ordway Research Institute from 2009. His research has attracted attention across the field of study and has been published in various media outlets such as impactjournals.com. His work has become an inspiration to his peers and students who will continue to build on his work after he is gone. His research in the relationship between oncology and anti aging has shown that certain drugs for cancer treatment are used to protect the healthy cells from damage from either the cancerous cells or the treatment to eradicate the diseased cells. He postulates that TOR signaling, a successful treatment regimen for cancer treatment and designing new drugs for combating cancer could have ground breaking uses in the field of anti aging.
To support his stance Blagosklonny has done extensive research in a variety of fields including, targeted cancer therapy, general traditional cancer therapy, anti aging drug applications, and biogerontology. His work is particularly inspiring because of his hopes for its application. Blagosklonny hopes to develop a treatment for cancer that does not damage the surrounding cells. It would eliminate the dangerous cancerous cells while leaving the healthy cells intact. This would not only help patients with pain and avoiding unnecessary tissue damage but would also lead to increase recovery speeds for the patients because their bodies would still have the necessary healthy tissue and cells to begin regeneration faster.
Financially, Blagosklonny hopes to help make the treatment more affordable. His hope is that cancer treatment will cease to be a luxury for the rich but will become a commonplace practice that will be available to anyone who needs it. Blagosklonny not only continues to develop his own research and advancements but also acts as the chief medical editor for two major medical journals, Cell Cycle and Oncotarget. This platform has helped him inspire many of his peers and students to continue with his research and help realize his dream of affordable cancer treatment that can also be used to alleviate the damage that occurs as a result of aging. His research and advancements in these areas of study have helped usher in a new age of discovery that could very soon see his dreams for a cost effective and painless cancer treatment become a reality for everyone no matter where they are from or what their status in society might be.